3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Gastroparesis
1
Esophageal Motility Disorders
1
Esophageal Diseases
1
Esophageal Achalasia
1
Interventions
Cisplatin
22
pembrolizumab
17
Drug Therapy
16
Carboplatin
15
Paclitaxel
12
Dexamethasone
12
Gemcitabine
11
Magnetic Resonance Spectroscopy
10
Bevacizumab
10
Docetaxel
9
venetoclax
8
atezolizumab
8
Pemetrexed
8
Oxaliplatin
8
Specimen Handling
7
Radiotherapy
7
Nivolumab
7
Cyclophosphamide
7
Capecitabine
7
Methotrexate
6
130-nm albumin-bound paclitaxel
6
durvalumab
5
blinatumomab
5
Cytarabine
5
Androgen Antagonists
5
tislelizumab
4
spartalizumab
4
pertuzumab
4
Vincristine
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Recruiting
×
Botulinum Toxins, Type A
×
Clear all
NCT06721520
2026-02-25
EMPTY
The Cleveland Clinic
Phase 2/3
Recruiting
170 enrolled